Pountain G D, Keogan M T, Brown D L, Hazleman B L
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom.
Ann Rheum Dis. 1993 Oct;52(10):730-3. doi: 10.1136/ard.52.10.730.
Some reports have described a decreased percentage of circulating CD8+ cells in patients with polymyalgia rheumatica and giant cell arteritis (PMR/GCA) before treatment and persisting for some months during treatment with corticosteroids. Other studies have found no such changes. There are overt methodological variations between these studies and there may also hidden differences, such as the timing of blood samples. The purpose of this study was to investigate T cell subtypes in patients with PMR/GCA while controlling for variables known to affect T cells.
Circulating T cell subsets were measured in 36 patients with PMR/GCA before and during treatment with prednisolone. Blood samples during treatment were taken before the daily dose of prednisolone. The whole blood lysis method was used followed by flow cytometry.
Compared with controls, CD8+ cells were not reduced before treatment in patients with PMR/GCA (0.44 x 10(9)/l; 28% of lymphocytes). CD4+ cells were also normal (0.78 x 10(9)/l; 48% of lymphocytes). During treatment with prednisolone total T cells increased from 1.18 to 1.59 x 10(9)/l and CD4+ cells increased from 0.78 to 1.05 x 10(9)/l. The percentage of CD8+ cells decreased on treatment from 28 to 25%.
This study does not confirm the finding of some groups that the percentage of circulating CD8+ cells is reduced in patients with PMR/GCA before treatment. It does show that the percentage of CD8+ cells decreases during treatment with corticosteroids. This needs to be considered when designing studies of lymphocyte subsets in diseases treated with corticosteroids.
一些报告描述了风湿性多肌痛和巨细胞动脉炎(PMR/GCA)患者在治疗前循环CD8+细胞百分比降低,且在使用糖皮质激素治疗期间持续数月。其他研究未发现此类变化。这些研究之间存在明显的方法学差异,也可能存在隐藏差异,如血样采集时间。本研究的目的是在控制已知影响T细胞的变量的同时,调查PMR/GCA患者的T细胞亚群。
在36例PMR/GCA患者使用泼尼松龙治疗前及治疗期间测量循环T细胞亚群。治疗期间的血样在每日泼尼松龙剂量前采集。采用全血裂解方法,随后进行流式细胞术检测。
与对照组相比,PMR/GCA患者治疗前CD8+细胞未减少(0.44×10⁹/L;占淋巴细胞的28%)。CD4+细胞也正常(0.78×10⁹/L;占淋巴细胞的48%)。在泼尼松龙治疗期间,总T细胞从1.18增加至1.59×10⁹/L,CD4+细胞从0.78增加至1.05×10⁹/L。治疗期间CD8+细胞百分比从28%降至25%。
本研究未证实一些研究组的发现,即PMR/GCA患者治疗前循环CD8+细胞百分比降低。研究确实表明,糖皮质激素治疗期间CD8+细胞百分比降低。在设计用糖皮质激素治疗的疾病的淋巴细胞亚群研究时,需要考虑这一点。